A black eye for Vision Eye

Company could be gearing up for a transformation of its business

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vision Eye Institute (ASX:VEI) has seen its shares slammed, at one stage down 23%, after the company reported a $16.9 million loss for the 2013 financial year.

Excluding goodwill impairment, Vision Eye reported a profit after tax of $9.4 million, up 5.6% compared to the previous year. The company took a $26.3 million impairment on goodwill, arising from a reduction to forecast earnings from New South Wales.

Revenues were down 3.7% to $107.1 million, thanks to changes to health fund rebates, exit from the Mackay day surgery business in January 2012, and most worryingly, continued decline in discretionary refractive revenues. As retailers David Jones (ASX:DJS) and Myer Holdings (ASX:MYR) are experiencing, consumers are keeping their hands in their pockets when it comes to discretionary purchases. That includes spending money on eye surgery to reduce the reliance on glasses and contact lenses.

Pleasingly, finance costs dropped 24.4%, as gross bank debt fell from $85 million in 2012 to $47.5 million, and the group benefitted from lower interest rates. Debt has been dropping consistently since 2008, and at the end of July 2013, Vision Eye reports that it had just $37 million in net bank debt.

Day surgery growth continues, with theatre revenues now accounting for 34% of total group revenue, after rising 6%, reflecting increasing demand for non-discretionary surgical procedures. Surgical revenues rose 5%, consistent with the trend in theatre revenue.

Moving to the outlook for the next financial year, Vision Eye says its priority is driving greater utilisation of its day surgeries, and can now consider expanding its footprint – we assume through acquisitions.

Foolish takeaway

Despite today's fall, Vision Eye has outperformed the S&P /ASX Index (Index:^AXJO) (ASX:XJO) over the past year, rising close to 30%, compared to the index return of 20%. Investors might want to keep an eye on Vision Eye – it may be about to metamorphosize away from eye surgery into a day surgery business.

Interested in our #1 dividend-paying stock? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."

More reading


Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »